Literature DB >> 26003403

The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study.

Angel Asensio1, Stefano Di Bella2, Andrea Lo Vecchio3, Santiago Grau4, Warren M Hart5, Beatriz Isidoro6, Ricardo Scotto3, Nicola Petrosillo2, Maureen Watt7, Jameel Nazir7.   

Abstract

OBJECTIVE: To assess the impact of Clostridium difficile infection (CDI) on hospital resources and costs in Spain and Italy.
METHODS: CDI data were collected from institutions in Spain and Italy. Each patient was matched with two randomly selected uninfected controls in the same institution. Patient outcomes were assessed for the first and second episodes of CDI and for patients aged ≤65 and >65 years. The impact of CDI on hospital length of stay (LOS) was used to calculate CDI-attributable costs. A multivariate analysis using duration of stay as the continuous outcome variable assessed the independent effect of CDI on hospital costs and LOS.
RESULTS: LOS attributable to CDI ranged from 7.6-19.0 days in adults and was 5.0 days in children; the increases were greater in adults in Italy than in Spain. Attributable costs per adult patient ranged from €4396 in Madrid to €14 023 in Rome, with the majority of the cost being due to hospitalization. For children, the total attributable cost was €3545/patient.
CONCLUSIONS: These data show that the burden of CDI is considerable in Spain and Italy. Treatments that can reduce LOS, disease severity, and recurrence rates, as well as effective infection control measures to prevent transmission, have the potential to reduce the burden of CDI.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  CDI; Clostridium difficile infection; Cost burden; Hospital length of stay; Matched cohort analysis

Mesh:

Year:  2015        PMID: 26003403     DOI: 10.1016/j.ijid.2015.05.013

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  11 in total

1.  Age and gender differences in Clostridium difficile-related hospitalization trends in Madrid (Spain) over a 12-year period.

Authors:  M D Esteban-Vasallo; S Naval Pellicer; M F Domínguez-Berjón; M Cantero Caballero; Á Asensio; G Saravia; J Astray-Mochales
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-07       Impact factor: 3.267

Review 2.  Gastrointestinal and liver infections in children undergoing antineoplastic chemotherapy in the years 2000.

Authors:  Elio Castagnola; Eliana Ruberto; Alfredo Guarino
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy.

Authors:  Daniele Roberto Giacobbe; Valerio Del Bono; Malgorzata Mikulska; Giulia Gustinetti; Anna Marchese; Federica Mina; Alessio Signori; Andrea Orsi; Fulvio Rudello; Cristiano Alicino; Beatrice Bonalumi; Alessandra Morando; Giancarlo Icardi; Sabrina Beltramini; Claudio Viscoli
Journal:  Infection       Date:  2017-08-30       Impact factor: 3.553

4.  Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.

Authors:  Haruhisa Fukuda; Takahisa Yano; Nobuyuki Shimono
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

5.  Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country.

Authors:  A Lo Vecchio; L Lancella; C Tagliabue; C De Giacomo; S Garazzino; M Mainetti; L Cursi; E Borali; M V De Vita; E Boccuzzi; L Castellazzi; S Esposito; A Guarino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

Review 6.  Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value.

Authors:  Amanda R D'Ostroph; Tsz-Yin So
Journal:  Infect Drug Resist       Date:  2017-10-19       Impact factor: 4.003

7.  Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.

Authors:  Vimalanand S Prabhu; Oliver A Cornely; Yoav Golan; Erik R Dubberke; Sebastian M Heimann; Mary E Hanson; Jane Liao; Alison Pedley; Mary Beth Dorr; Stephen Marcella
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

8.  Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.

Authors:  Emilio Bouza; Oliver A Cornely; Antonio Ramos-Martinez; Robert Plesniak; Misoo C Ellison; Mary E Hanson; Mary Beth Dorr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-06-06       Impact factor: 3.267

Review 9.  Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review.

Authors:  Akshita Gupta; Ashwin N Ananthakrishnan
Journal:  Therap Adv Gastroenterol       Date:  2021-05-30       Impact factor: 4.409

10.  Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.

Authors:  E Bouza; J Cobo; M J Rodríguez-Hernández; M Salavert; J P Horcajada; J A Iribarren; E Obi; V Lozano; S Maratia; M Cuesta; E Uría; E Limón
Journal:  Rev Esp Quimioter       Date:  2021-02-23       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.